An interventional study of HII-Training (HIIT) 6 Months and Cardiopulmonary exercise testing in Leukemia, HIIT and Sport, sponsored by University of Erlangen-Nürnberg Medical School. Not yet recruiting at 1 site in Germany. Open to participants aged 6 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Leukemia with a site in Germany — 19 open to participants now, 27 under way, 7 of them phase 3. Leukemia · Germany.
Among the 139 studies in Leukemia with a site in Germany, this one is the 76th largest by planned enrollment of the 122 interventional ones that give a count, is the only one that started in 2027, is one of 9 with no phase, reaches primary completion later than 13 of the 26 other live ones, and was the 139th registered.
2,382 studies on the registry are indexed under Leukemia; 254 are open to participants now.
Browse Leukemia studies →19 of the 139 studies in Leukemia with a site in Germany are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Germany, United States, Australia and 14 more countries
Ages 1–18
AvenCell Therapeutics, Inc. · Sites in Germany, United States
Ages 18+
Princess Maxima Center for Pediatric Oncology · Sites in Germany, Austria, Belgium and 11 more countries
Ages 1–21
Princess Maxima Center for Pediatric Oncology · Sites in Germany, Austria, Belgium and 11 more countries
Ages 1–21
Kura Oncology, Inc. · Sites in Germany, United States, Australia and 14 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 208 Leukemia studies recruiting now, 112 (54%) set no upper age limit and 74 (36%) stop at 75 or younger; 86 take children under 18; 24 take healthy volunteers.
This study: 6 Years to 10 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 59 · Phase 3 50 · Phase 4 3
First in 1993; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 40 across 1,770 interventional studies indexed under Leukemia.
Median enrollment 177 across the 122 interventional studies, 113 across the 10 observational. Of the 88 that completed or were terminated, 49 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
83 of 139 have an industry lead sponsor. The 10 most frequent:
University of Erlangen-Nürnberg Medical School is the lead sponsor of 277 studies on the registry; 53 are open to participants now.
University of Erlangen-Nürnberg Medical School has 3 studies filed under Leukemia — fewer than ten, so there is no comparison to draw.
6 of the studies in Leukemia with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03836261Phase 3Acerta Pharma BVStudy of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | 2027-04-30 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT05475925Dren BioA Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | 2026-12 |
| NCT05235633Technical University of MunichADLs at the End of Acute Treatment for Childhood Leukemia and Non-Hodgkin Lymphoma | 2027-07-31 |
| NCT04466059Munich Leukemia LaboratoryBetter Leukemia Diagnostics Through AI (BELUGA) | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 139 studies in Leukemia with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, the investigators aim to examine the effects of high-intensity interval training (HIIT) on cardiopulmonary fitness and immunological recovery in female ALL survivors who underwent cancer treatment during childhood and adolescence.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Total of 6 months of HIIT
Behavioral: HII-Training (HIIT) 6 Months · Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: Echocardiography · Diagnostic Test: Electrocardiography (EKG) · Diagnostic Test: blood draw · Diagnostic Test: Questionnaire · Diagnostic Test: MSOT
3 months without intervention followed by 3 months of HIIT
Diagnostic Test: Cardiopulmonary exercise testing · Diagnostic Test: Echocardiography · Diagnostic Test: Electrocardiography (EKG) · Diagnostic Test: blood draw · Diagnostic Test: Questionnaire · Diagnostic Test: MSOT · Behavioral: HIT-Training (HIIT) 3 Months
HIIT should be done at least 2-3 times per week. Each session's duration is 60 minutes including warm-up and cool-down. Study participation will be monitored.
Treadmill Exercising Test
Echocardiography with strain rate imaging
Routine Electrocardiography
Comprehensive fluorescence activated cell sorting (FACS) systematically assessing immune reconstitution of T-, B-, and NK cells after termination of intensive chemotherapy (5ml)
QoL: Kid-KINDL
Multispectral-optoacustic imaging of the calf muscle
HIIT should be done at least 2-3 times per week. Each session's duration is 60 minutes including warm-up and cool-down. Study participation will be monitored.
VO2
Oxygen uptake (VO2)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
VO2max
peak oxygen uptake (VO2max)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
RER
Respiratory exchange ratio (RER)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
VT2
Ventilatory anaerobic threshold (VT2)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
VCO2
Carbon dioxide output (VCO2)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
HR
Heart rate (HR)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
HRR
Heart Rate Reserve (HRR)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Breath rate at VAT
Breath rate at VAT
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
BRR
Breath rate reserve (BRR)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
VE
minute ventilation (VE)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
O2 Pulse
O2 Pulse
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
HRV
Heart rate variability (HRV)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Echocardiography
Myocardial function by echocardiographic strain and strain-rate imaging
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Age
Age in years
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Gender
Gender
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Weight
Weight
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Blood pressure
Blood pressure measurement
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
QoL
Quality of Life: Kid-KINDL
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Immune reconstitution (IR)
T-, B- and natural killer cell count and marker expression profiles in FACS Blood sample (5ml)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Oxygenated haemoglobin (HbO₂, MSOT)
Oxygenated haemoglobin (HbO₂)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Deoxygenated haemoglobin (HHb, MSOT)
Deoxygenated haemoglobin (HHb)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Total haemoglobin (tHb, MSOT)
Total haemoglobin (tHb)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Tissue oxygen saturation (sO₂, MSOT)
Tissue oxygen saturation (sO₂)
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Signal Intensity (SI, MSOT)
MSOT signal intensity per region of interest
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
MSOT topogram of perfusion of the m. gastrocnemius
MSOT topogram of perfusion of the m. gastrocnemius
Time frame: 3 Time points: First evaluation: Before Randomization Second evaluation: 3 months after randomization Third evaluation: 6 months since after randomization
Plan to share: Yes — The raw, individual and identifiable patient data are protected and are not available due to data privacy laws. Further data sets are planned to be shared
Supporting information: Study protocol, Statistical analysis plan
Time frame: Beginning 9 months and ending 36 months following article publication
Access criteria: The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request as follows: Individual participant data will not be available Study Protocol and Statistical Analysis Plan will be available The data will be available beginning 9 months and ending 36 months following article publication. The data will be available to researchers who provide a methodologically sound proposal. The data will be available for individual participant data meta-analysis, only. Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at https://www.uk-erlangen.de. Restrictions may apply due to patient privacy and the General Data Protection Regulation.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jul 2028, 18 months later.
Of 103 non-industry interventional studies with no phase under Leukemia, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 128. This study's planned 18 months is below that.
Counting every sponsor, half of 110 studies reached it within 38 months; a quarter within 22 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Erlangen-Nürnberg Medical School →